Forepont Capital Partners

Okeiro is a technology company specializing in AI-driven solutions for chronic disease and transplant care. It develops predictive algorithms, specifically for kidney transplantation, to assess long-term organ failure risk and personalize treatment plans. The company's platform integrates algorithms and clinical data to facilitate informed decision-making, streamline clinical workflows, and enhance patient care.

AlterDiag is a medical technology company that specializes in the development and commercialization of innovative lateral flow immunochromatographic tests. These tests utilize single-chain variable fragment antibodies, enabling rapid and cost-effective diagnostic solutions for healthcare professionals and patients. AlterDiag's products are designed to be user-friendly, suitable for both healthcare centers and home use, facilitating personalized care and prompt medical response.

GPN Vaccines is a clinical-stage biotechnology company focused on developing a vaccine against Streptococcus pneumoniae, a leading cause of pneumonia, bacteremia, meningitis, and otitis media. The company's innovative vaccine utilizes a gamma-irradiation process to inactivate and kill the bacteria while preserving the surface protein antigens. This method aims to enhance the immune response, offering improved protection against pneumococcal infections. GPN Vaccines seeks to address a critical public health need by providing a vaccine that can significantly reduce the impact of this serious bacterial pathogen.

GPN Vaccines is a clinical-stage biotechnology company focused on developing a vaccine against Streptococcus pneumoniae, a leading cause of pneumonia, bacteremia, meningitis, and otitis media. The company's innovative vaccine utilizes a gamma-irradiation process to inactivate and kill the bacteria while preserving the surface protein antigens. This method aims to enhance the immune response, offering improved protection against pneumococcal infections. GPN Vaccines seeks to address a critical public health need by providing a vaccine that can significantly reduce the impact of this serious bacterial pathogen.

Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.

Mobius Biomedical plans to bring unprecedented efficiencies to the development and manufacturing of biologics and biosimilars, and reduce their cost by over 90% at commercial scale. The Company has developed new design, new process and new equipment to drastically reduce the capex, opex and facility footprint of manufacturing plants while maintaining the purity, throughput and efficiency at commercial scale.

Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.

GPN Vaccines is a clinical-stage biotechnology company focused on developing a vaccine against Streptococcus pneumoniae, a leading cause of pneumonia, bacteremia, meningitis, and otitis media. The company's innovative vaccine utilizes a gamma-irradiation process to inactivate and kill the bacteria while preserving the surface protein antigens. This method aims to enhance the immune response, offering improved protection against pneumococcal infections. GPN Vaccines seeks to address a critical public health need by providing a vaccine that can significantly reduce the impact of this serious bacterial pathogen.

BayBridgeDigital Group LLC, established in 2017, is a New York-based digital advisory and consulting firm with additional offices in Paris and Tel Aviv. It specializes in digital transformation services, including e-commerce, digital marketing, mobile solutions, data analytics, AI, Salesforce integration, and software development. The company serves clients from various industries such as retail, energy, healthcare, and finance, helping them achieve business value through digital solutions. BayBridgeDigital's approach combines design-led strategies with expertise in the Salesforce ecosystem to deliver exceptional results and accelerate digital transformations.